2010 Volume 25 Issue 5 Pages 310-316
To promote antimicrobial use based on the pharmacokinetics/pharmacodynamics (PK/PD) properties, our infection control team (ICT) and the department of pharmacy developed materials concerning the PK/PD properties of antimicrobial agents, and began distribution to our hospital in April 2008. At the same time, we tried to explain the PK/PD properties by holding study meetings, delivering ICT news, and revising the indications for antimicrobial agents. Since the beginning in fiscal 2008, the mode of administration of 1000 mg×3 times/day has increased for cefozopran (CZOP), the mode of administration of 500 mg×3 times/day has increased for meropenem (MEPM), and the mode of administration of 250 mg×3 times/day and 500 mg×3 times/day has increased for doripenem (DRPM). Moreover, the average dosage period of the fourth generation cephems, carbapenems, new quinolone agents, and anti-MRSA agents was shortened in fiscal 2008-2009 compared with fiscal 2006-2007. The rate of resistance for Pseudomonas aeruginosa (P. aeruginosa) to CZOP increased in fiscal 2006-2007 compared with fiscal 2005, but decreased to the same level as fiscal 2005 in fiscal 2008-2009. Moreover, the rate of resistance for P. aeruginosa to MEPM decreased every year. Therefore, our promotion efforts were useful for the practice of antimicrobial use based on PK/PD properties. In addition, the possibility of reducing the treatment period of infectious disease and prevention of increase in the antimicrobial resistant bacteria can be achieved by the practice of antimicrobial use based on PK/PD properties.